BQ Journal Vol 47 - Q2 2022 - 30

Morbidity and Mortality Weekly Report
Program (4). Because only the first dose of a 2-dose primary
vaccination series or the single dose for Janssen vaccine was
analyzed, the total number of doses per county was capped at
the county's population size.†† Primary series completion§§
was also calculated and stratified by urban-rural classification.
Among those aged ≥12 years who had completed their
primary COVID-19 vaccination series, the proportions eligible
for a booster dose and with sufficient time to receive it,¶¶ as
well as the proportions of eligible persons who did and did
not receive a booster dose, were calculated and stratified by
urban-rural classification. Tests for statistical significance were
†† For statistical analysis, the number of doses per county was capped at the county's
population size minus one for a maximum vaccination coverage of 100%.
§§ Primary series completion is defined as receiving either both doses of a 2-dose
mRNA COVID-19 vaccination series (Pfizer-BioNTech or Moderna) or a
single dose of the Janssen vaccine. Series completion includes receipt of the
same vaccine type for both mRNA doses or mismatched products for the first
and second dose (e.g., Pfizer-BioNTech for the first dose and Moderna for
the second dose, or vice versa).
¶¶ Eligible population is defined as persons aged ≥12 years who completed a primary
COVID-19 vaccination series and were eligible to receive a booster or additional
primary dose by the end of the analysis period, January 31, 2022. Those aged
12-17 years were eligible to receive their booster dose beginning January 5,
2022, and persons aged ≥18 years were eligible beginning November 19, 2021.
These differences in eligibility dates were accounted for in analyses by restricting
data to these eligibility dates by age. For Pfizer-BioNTech and Moderna vaccines,
the primary series must have been completed by August 31, 2021 (i.e., ≥5 months
earlier); for Janssen recipients, 1 dose must have been received by December 1,
2021 (i.e., ≥2 months earlier).
not conducted because the data represent the U.S. population
(excluding eight counties in California) and were not based on
population samples. All analyses were conducted using SAS
software (version 9.4; SAS Institute). This activity was reviewed
by CDC and was conducted consistent with applicable federal
law and CDC policy.***
Overall, during December 14, 2020-January 31, 2022, rural
counties had lower first-dose vaccination coverage (58.5%) than
did urban counties (75.4%) (Table 1). Females and males had
lower first-dose coverage in rural counties (61.4% and 55.7%,
respectively) than in urban counties (77.6% and 73.2%, respectively).
Among all age groups, vaccination coverage with ≥1 doses
was lower in rural counties, with the largest absolute difference
(26.2 percentage points) among those aged 12-17 years (38.7%
rural, 64.9% urban) and the largest relative difference among
those aged 5-11 years (14.7% rural, 30.5% urban). Across
jurisdictions, vaccination coverage with ≥1 doses varied by
urban-rural classification. Among jurisdictions for which the
urban-rural classification could be calculated, 46 jurisdictions
had higher coverage in urban than rural counties, and one
jurisdiction (Arizona) had higher coverage in rural than urban
counties (Table 2). Primary series completion was lower in rural
counties (52.1%) than in urban counties (66.2%) (Table 3).
*** 45 C.F.R. part 46.102(l)(2); 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d);
5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.
TABLE 1. COVID-19 vaccination coverage for persons aged ≥5 years who have received their first dose of the Moderna or Pfizer-BioNTech
vaccine or a single dose of the Janssen (Johnson & Johnson) vaccine,* by sex, age group, and urban-rural classification† - United States,
December 14, 2020-January 31, 2022
No. (%)
Characteristic
Total
Sex
Male
Female
Age group, yrs
5-11
12-17
18-64
≥65
Overall
226,621,879
(73.1)
107,681,923
(70.7)
118,939,956
(75.4)
8,046,457
(28.4)
15,398,653
(61.3)
152,499,838
(75.9)
50,676,931
(91.1)
Large central
metropolitan
76,387,928
(80.4)
36,514,502
(78.7)
39,873,426
(82.0)
3,007,534
(34.7)
5,419,083
(73.0)
54,096,094
(84.4)
13,865,217
(93.5)
Large fringe
metropolitan
59,624,160
(76.1)
28,228,944
(73.6)
31,395,216
(78.6)
2,363,850
(32.5)
4,346,283
(65.4)
40,059,543
(79.1)
12,854,484
(93.7)
Six-level urban-rural classification
Medium
Small
metropolitan
47,054,083
(72.2)
22,236,671
(69.6)
24,817,412
(74.7)
1,591,017
(26.3)
3,203,152
(59.9)
30,972,242
(74.4)
11,287,672
(93.0)
metropolitan Micropolitan Noncore
18,185,028
(64.4)
8,633,027
(61.9)
9,552,001
(66.8)
517,209
(20.4)
1,080,652
(48.5)
11,706,128
(65.3)
4,881,039
(87.6)
15,549,920
(60.4)
7,393,069
(57.6)
8,156,851
(63.2)
373,368
(16.1)
866,250
(41.7)
9,782,658
(61.0)
4,527,644
(85.4)
9,820,760
(55.8)
4,675,710
(52.8)
5,145,050
(58.8)
193,479
(12.5)
483,233
(34.2)
5,883,173
(55.7)
3,260,875
(80.2)
Urban
201,251,199
(75.4)
95,613,144
(73.2)
105,638,055
(77.6)
7,479,610
(30.5)
14,049,170
(64.9)
136,834,007
(78.5)
42,888,412
(92.7)
Rural
25,370,680
(58.5)
12,068,779
(55.7)
13,301,901
(61.4)
566,847
(14.7)
1,349,483
(38.7)
15,665,831
(58.9)
7,788,519
(83.2)
* Excludes doses with state of residence reported as a territory, freely associated state, or county of residence in California with population <20,000. Completeness
of county data varied by jurisdiction.
† First doses of COVID-19 vaccine were matched by county of residence to one of six urban-rural categories according to the 2013 National Center for Health Statistics
Urban-Rural Classification Scheme (https://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf). To further classify counties into two categories (urban versus rural),
four of these six categories were combined into urban areas (large central metropolitan, large fringe metropolitan, medium metropolitan, and small metropolitan),
and two were combined into rural areas (micropolitan and noncore).
Two-level urban-rural
classification
336
MMWR / March 4, 2022 / Vol. 71 / No. 9
US Department of Health and Human Services/Centers for Disease Control and Prevention
Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News
30
A Henry Schein Publication
https://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf
BQ Journal Vol 47 - Q2 2022

Table of Contents for the Digital Edition of BQ Journal Vol 47 - Q2 2022
